NATERA INC

NTRA represents Natera, Inc., a diagnostics company focused on genetic testing and oncology. It develops cell-free DNA tests used in prenatal screening, organ transplant monitoring, and cancer detection and treatment monitoring. Its products help clinicians assess genetic conditions and disease status using blood samples.

NTRA trades on the Nasdaq Global Select Market under the ticker symbol NTRA. Being listed on a major U.S. exchange means the shares are available to U.S. investors during regular market hours and subject to Nasdaq listing and reporting standards.

The most current NTRA price, along with daily changes, volume, and intraday movement, is displayed on this stock detail page. Because prices update continuously during trading hours, review the latest quote there rather than relying on older figures.

Valuation for NTRA typically relies on metrics suited to a diagnostics company with growth characteristics, such as price-to-sales, enterprise value to revenue, and comparisons to peer lab and genetic testing firms. Because profitability can be uneven, earnings-based ratios like P/E may be less informative; current valuation figures should be checked on this page.

Review NTRA's quarterly and annual filings for revenue growth, gross margin, operating expenses, and progress toward profitability. Oncology and transplant testing volumes, reimbursement trends, and cash burn are also important. These figures appear in SEC filings and earnings releases; updated results are summarized on this page.

NTRA faces risks tied to reimbursement and payer coverage decisions, competition in genetic testing, clinical study outcomes, regulatory changes, and the need to manage operating costs while expanding test adoption. Share price can also be sensitive to quarterly results and shifts in demand for oncology and prenatal testing.